Returns, Recall, Accountability and Destruction

A clinical trial's product story does not end with the last patient's last dose; the real test comes when the trial closes: can the fate of every unit that arrived be shown one by one? Accountability is the management discipline of exactly that question. Across the trial, the quantities received into the depot, distributed to sites, given to patients, returned and destroyed must balance; where there is a difference, there must be an explanation. This chain starts with returns: unused products come back to the depot under defined conditions. On a quality defect, recall engages: the product, whether in the field or the depot, is collected back through a single point. At closure, destruction remains: every unused product is eliminated through a permitted and witnessed process. This article explains the rules of the four processes, their record requirements and their interconnection. A map of the closure file is offered for sponsors, CROs, depot and site teams.

Who is this for?

This guide is for every role looking at the end of the research products' life cycle. Sponsor teams, as the ultimate owner of accountability, await the closure reconciliation. CROs plan and run the return and destruction operations. Depot teams apply the return acceptance conditions and manage quarantine and pre-destruction stocks. Site coordinators and investigators keep patient-level distribution and return records; the fate of every box in the field sits in their ledger. Quality units manage the recall decision and the destruction approval. Regulatory teams carry the product fate information into the authority's closure notifications. Finance teams track destruction and return costs in the trial budget. In an audit the chain reads in one direction: from import to the patient and to every unit remaining after the patient. Each role must keep its own segment ready; closure is the file's most questioned section.

Which products does it cover?

The scope is all pharmaceutical products moving within the trial. Unused stocks of the investigational product, partially used packages, leftovers of comparator products, placebos, blinding remnants and ancillary medicine residues. Alongside these, sample and analysis materials and empty packages returning from the field are within the record scope; even an empty box is accountability evidence. Each product category carries its own rules: the investigational product and comparator enter the full accountability chain; placebo is monitored with the same discipline; ancillary medicines can be managed with a lighter record depending on the protocol definition. For temperature-sensitive products, return acceptance looks at the temperature record; a return without a record is not accepted. Sample materials sit in the closure file together with analysis results. Product-based expiry management also enters the scope: expired stock, even if unused, is taken into the destruction plan.

When does it apply?

The return process applies at every site closure and at the trial-end collection; in early-terminated centres the same flow runs. Destruction comes onto the agenda when the trial's product phase completes and reconciliation is secured; partial destruction is also possible when depot capacity or continuity requires. Recall, by contrast, is an exceptional process with two triggers: suspected quality defect or a safety issue. When a recall decision is taken, the answer to where the product sits is read from the accountability records; in an unrecorded chain a recall cannot be managed. The triggers live throughout the duration: a site closing, an investigator leaving, product expiring, relocation and depot change. Every trigger requires the records' update. Even in non-urgent situations an annual reconciliation is advisable: a count made mid-trial lightens the inevitable closure load at the end.

Legal framework and authority

The frame comes from the product management provisions of the clinical trials legislation and the arrangements for the keeping and destruction of medicines. The recording, reconciliation and destruction of research products are defined in this frame; the destruction of products not in circulation or unlicensed is subject to the relevant authority's processes. The competent authority is TİTCK: it oversees the accountability of research products, monitors destruction processes and regulates the notification procedures for recalls. In a recall, depending on the product's nature, other authorities and the customs side can engage; for a shipment still at customs the process merges with the halting of the import. The destruction operation itself is also subject to environmental and waste legislation: the elimination method and facility of pharmaceutical waste are notable. On the site side, records must be kept consistent with medical research ethics and file integrity rules. Current guides must be tracked on the authority's official pages, and closure notifications given with the content the legislation foresees.

Step-by-step process

1. Operate the accountability records from the trial's first day: keep quantities received, distributed, used, returned and destroyed at unit level.
2. Prepare the return plan at site closure: which products will come back, under what conditions they will travel, which will enter the field destruction scope.
3. Verify conditions at return acceptance: temperature record, packaging integrity and identity match; unconditional returns are not accepted.
4. Quarantine the returning products and label their statuses: return stock, out of use, awaiting destruction.
5. Build the reconciliation table: distribution minus use plus return per site must match the remaining stock; enter explanation records for differences.
6. Determine the destruction requirement and start the relevant authority process; the method, facility and date are planned.
7. Run the destruction with a witness: witness, method and quantity enter the minutes; visual recording, where required, is taken per procedure.
8. Write the recall scenario in advance: decision authority, communication chain, field instruction and record flow tested with a drill.
9. Complete the closure file: reconciliation tables, destruction minutes, return records and authority notifications archived in a single file.

Document checklist

• Unit-level accountability ledgers, site by site.
• Shipment and distribution records: delivery minutes, counter-signatures.
• Patient-level distribution records, consistent with the protocol version.
• Return acceptance minutes and temperature records.
• Quarantine labels and stock status reports.
• Reconciliation tables and difference explanation records.
• Destruction application and authority process documents.
• Destruction minute: quantity, method, date, witness.
• Recall plan and drill report.
• Closure notifications and archive layout.

Parties and responsibilities

The witness role should not be underestimated: the credibility of the destruction minute arises from the witness's independence. The responsibility matrix must also openly contain the destruction and recall rows.

Exceptions and edge cases

Practical questions pile up at the edges of closure processes. Partially used packages carry the question of return or destruction: practice generally does not want opened packages returned, holding them in the field and taking them into the destruction scope; the rule must be clarified in the sponsor's procedure. Returns whose cold chain cannot be documented fail at depot acceptance; the product is written into a field destruction plan. Expired stock can be destroyed while the trial continues; this runs as a partial destruction process. In early-terminated centres, taking the site records complete is closure's expensive step; if the investigator has left, the records are bound with a handover minute. In a recall, for goods still at customs, the halting of the import and the fate of the goods are managed separately. Where blinding has been opened, the status of remaining products changes; open-label return and destruction records are arranged accordingly. Ancillary medicine residues can be managed flexibly per the protocol definition; but no category can be left unrecorded. For products with biological waste character, the destruction method is subject to the additional conditions of environmental legislation.

Common mistakes

The most common mistake is leaving accountability to the trial's end; the reconciliation cannot be built and differences cannot be explained. The second is not checking conditions at return acceptance; damaged product enters the depot and stock credibility is dented. The third is running destruction without permission; the process counts as irregular and the closure notification weakens. The fourth is destroying without a witness; the minute loses credibility. The fifth is discarding empty packages and breaking the records; an empty box is evidence too. The sixth is writing a recall plan and leaving it undrilled; in a real event the communication chain does not work. The seventh is giving difference explanations verbally; an unrecorded explanation counts for nothing at audit. The eighth is archiving the closure file in a scattered way; if the answer to the question cannot be found in a single file, the file counts as absent.

Important notice

This article is general information, not legal or customs advice; for return, destruction and recall processes, the clinical trials legislation and TİTCK guides must govern. Product examples in the text are for orientation, and the GTİP examples are not binding. Destruction and notification procedures are subject to legislative change; official sources must be checked before any transaction.